proxalutamide proxalutamide proxalutamide (developmental code name gt-0918) is a nonsteroidal antiandrogen (nsaa) – specifically, a selective high-affinity silent antagonist of the androgen receptor (ar) – which is under development by suzhou kintor pharmaceuticals, inc., a subsidiary of kintor pharmaceutical limited, for the potential treatment of covid-19, prostate cancer, and breast cancer. it was approved in paraguay for the treatment of covid-19 in july 2021, but has not been approved at this time in other countries. proxalutamideclinical dataother namespruxelutamide; gt-0918routes ofadministrationby mouthdrug classnonsteroidal antiandrogenatc codenoneidentifiers iupac name 4-pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile cas number1398046-21-3pubchem cid60194102chemspider52084193uniiqx6o64gp40chemical and physical dataformulac24h19f4n5o2smolar mass517.50 g·mol−13d model (jsmol)interactive image smiles cc1(c(=o)n(c(=s)n1c2=cn=c(c=c2)cccc3=nc=co3)c4=c(c(=c(c=c4)c#n)c(f)(f)f)f)c inchi inchi=1s/c24h19f4n5o2s/c1-23(2)21(34)32(17-9-6-14(12-29)19(20(17)25)24(26,27)28)22(36)33(23)16-8-7-15(31-13-16)4-3-5-18-30-10-11-35-18/h6-11,13h,3-5h2,1-2h3key:kcbjgvdosbkvkp-uhfffaoysa-n research prostate cancer proxalutamide is in phase iii studies for mcrpc as monotherapy and in combination with abiraterone. in the united states, it is in phase ii study as monotherapy for mcrpc. other indications proxalutamide is in phase ic clinical trial in china.